Log in

NYSEAMERICAN:PLX - Protalix Biotherapeutics Stock Price, Forecast & News

-0.09 (-2.30 %)
(As of 02/21/2020 03:18 AM ET)
Today's Range
Now: $3.82
50-Day Range N/A
52-Week Range
Now: $3.82
Volume136,800 shs
Average Volume139,135 shs
Market Capitalization$56.68 million
P/E RatioN/A
Dividend YieldN/A
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Read More…

Industry, Sector and Symbol

Industry Biotechnology
Previous SymbolNYSEMKT:PLX



Sales & Book Value

Annual SalesN/A



Market Cap$56.68 million
Next Earnings Date3/16/2020 (Estimated)

Receive PLX News and Ratings via Email

Sign-up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter.

Protalix Biotherapeutics (NYSEAMERICAN:PLX) Frequently Asked Questions

What is Protalix Biotherapeutics' stock symbol?

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

When did Protalix Biotherapeutics' stock split? How did Protalix Biotherapeutics' stock split work?

Protalix Biotherapeutics shares reverse split on Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of Protalix Biotherapeutics stock prior to the reverse split would have 10 shares after the split.

How were Protalix Biotherapeutics' earnings last quarter?

Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.40) by $0.20. The company earned $14.25 million during the quarter, compared to the consensus estimate of $11.60 million. During the same quarter last year, the business posted ($1.00) earnings per share. View Protalix Biotherapeutics' Earnings History.

When is Protalix Biotherapeutics' next earnings date?

Protalix Biotherapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Protalix Biotherapeutics.

What price target have analysts set for PLX?

1 equities research analysts have issued 12-month target prices for Protalix Biotherapeutics' stock. Their forecasts range from $30.00 to $30.00. On average, they expect Protalix Biotherapeutics' share price to reach $30.00 in the next twelve months. This suggests a possible upside of 685.3% from the stock's current price. View Analyst Price Targets for Protalix Biotherapeutics.

What is the consensus analysts' recommendation for Protalix Biotherapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix Biotherapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Protalix Biotherapeutics.

What are Wall Street analysts saying about Protalix Biotherapeutics stock?

Here are some recent quotes from research analysts about Protalix Biotherapeutics stock:
  • 1. According to Zacks Investment Research, "Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. " (1/23/2020)
  • 2. HC Wainwright analysts commented, "We note that this would potentially involve Priority Review— i.e., a six-month review period vs. the roughly one-year time frame for standard review applications—for the pegunigalsidase alfa BLA. Over the last several months, Protalix and Chiesi have engaged the FDA in dialog on the eligibility of pegunigalsidase alfa for accelerated approval based on readily-available data generated by Protalix from its clinical studies of pegunigalsidase alfa. As a result of this dialog and based on the content of a recent letter received from the Chiesi have initiated preparations for a BLA submission based on data from the completed Phase 1/2 clinical trials of pegunigalsidase alfa and from the ongoing Phase 3 BRIDGE clinical trial. We consider this update a very positive development for Protalix and thus reiterate our Buy rating and 12-month target price of $3.00 per share." (6/10/2019)

Has Protalix Biotherapeutics been receiving favorable news coverage?

News articles about PLX stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Protalix Biotherapeutics earned a news impact score of 0.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Protalix Biotherapeutics.

Are investors shorting Protalix Biotherapeutics?

Protalix Biotherapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 373,000 shares, an increase of 39.8% from the January 15th total of 266,900 shares. Based on an average trading volume of 132,800 shares, the days-to-cover ratio is currently 2.8 days. Currently, 2.6% of the company's stock are short sold. View Protalix Biotherapeutics' Current Options Chain.

Who are some of Protalix Biotherapeutics' key competitors?

What other stocks do shareholders of Protalix Biotherapeutics own?

Who are Protalix Biotherapeutics' key executives?

Protalix Biotherapeutics' management team includes the folowing people:
  • Mr. Moshe Manor, CEO, Pres & Director (Age 63)
  • Dr. Yoseph Shaaltiel, Founder and Exec. VP R&D (Age 65)
  • Mr. Yossi Maimon CPA, CPA, MBA, CFO, VP, Treasurer & Sec. (Age 48)
  • Mr. Yaron Naos, Sr. VP of Operations (Age 55)
  • Dr. Einat Brill-Almon, Sr. VP of Product Devel. (Age 59)

Who are Protalix Biotherapeutics' major shareholders?

Protalix Biotherapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (3.10%), California Public Employees Retirement System (0.54%), Jane Street Group LLC (0.22%) and SG Americas Securities LLC (0.15%). View Institutional Ownership Trends for Protalix Biotherapeutics.

Which major investors are selling Protalix Biotherapeutics stock?

PLX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, California Public Employees Retirement System and SG Americas Securities LLC. View Insider Buying and Selling for Protalix Biotherapeutics.

Which major investors are buying Protalix Biotherapeutics stock?

PLX stock was bought by a variety of institutional investors in the last quarter, including Jane Street Group LLC. View Insider Buying and Selling for Protalix Biotherapeutics.

How do I buy shares of Protalix Biotherapeutics?

Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Protalix Biotherapeutics' stock price today?

One share of PLX stock can currently be purchased for approximately $3.82.

How big of a company is Protalix Biotherapeutics?

Protalix Biotherapeutics has a market capitalization of $56.68 million. Protalix Biotherapeutics employs 184 workers across the globe.View Additional Information About Protalix Biotherapeutics.

What is Protalix Biotherapeutics' official website?

The official website for Protalix Biotherapeutics is http://www.protalix.com/.

How can I contact Protalix Biotherapeutics?

Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.

MarketBeat Community Rating for Protalix Biotherapeutics (NYSEAMERICAN PLX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  205 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about Protalix Biotherapeutics and other stocks. Vote "Outperform" if you believe PLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Featured Article: Cash Flow

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel